Aptevo Therapeutics (APVO) Projected to Post Quarterly Earnings on Thursday

Aptevo Therapeutics (NASDAQ:APVO) is projected to announce its results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($3.72) per share for the quarter.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($5.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.02) by $0.71. On average, analysts expect Aptevo Therapeutics to post ($17.04) EPS for the current fiscal year and ($6.59) EPS for the next fiscal year.

Aptevo Therapeutics Stock Performance

Shares of APVO opened at $1.36 on Wednesday. The company’s 50 day simple moving average is $1.81 and its 200-day simple moving average is $4.33. Aptevo Therapeutics has a 12-month low of $1.25 and a 12-month high of $28.08.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday, October 29th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, Aptevo Therapeutics currently has an average rating of “Sell”.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc is a biotechnology company developing targeted immunotherapies for cancer and other serious diseases. The company is headquartered in Seattle, Washington, and was established in 2016 as a spin-off from Emergent BioSolutions.

Aptevo’s research is based primarily on its ADAPTIR and ADAPTIR-FLEX antibody platforms, which are designed to create bispecific immune-cell engagers. These therapies are intended to connect immune cells with cancer cells or activate immune pathways to produce a targeted response.